Intellijoint Surgical Inc. and Vena Medical awarded $5.8 million from Ontario’s Life Sciences Scale-Up Fund
Two University of Waterloo–affiliated health-tech companies secure major provincial investment to bring lifesaving innovations to market
Two University of Waterloo–affiliated health-tech companies secure major provincial investment to bring lifesaving innovations to market
By University RelationsTwo University of Waterloo-affiliated companies are the first recipients of Ontario’s new Life Sciences Scale-Up Fund (LSSUF). Intellijoint Surgical Inc., a company founded by Waterloo alumni and Vena Medical, a Velocity Health company, will receive a combined $5.8 million to increase manufacturing capacity, expand globally and advance commercialization of their health-care technologies.
Vena is part of the Velocity Health stream, which supports early-stage startups in validating and commercializing medical and health-related technologies. While not a Velocity company, Intellijoint collaborates regularly with Velocity and the wider Waterloo innovation ecosystem.
“As one of Canada’s strongest health-technology commercialization platforms, it is great to see our Velocity founders making great strides towards improving health-care delivery,” says Moazam Khan, managing director of Venture Scale and Strategy at Velocity. “This sort of investment makes a big difference in supporting growing health-tech companies accelerate their path to market.”
The $24 million LSSUF is part of the Government of Ontario’s larger investment to strengthen the province’s biomanufacturing sector, accelerate innovation and attract further investment in life sciences.
Intellijoint Surgical, a leading provider of orthopaedic medical technologies, has supported more than 80,000 hip and knee replacements globally. The company will receive $1.3 million to integrate artificial intelligence and automation into its production and distribution workflows. This investment supports 34 existing positions and creates three new high-skilled roles.
Vena Medical develops intravascular imaging technologies used by physicians during stroke interventions and real-time diagnostics. The company has received $4.5 million from the LSSUF to establish its new Manufacturing Centre of Excellence in Kitchener. The funding supports nine existing jobs and creates 13 new high-skilled positions.
"Our team has engineered a highly complex, microscopic medical device, and now we have the state-of-the-art cleanroom and manufacturing infrastructure to build it at scale," says Phillip Cooper (BASc ’17), co-founder & COO of Vena Medical. "With the backing of the LSSUF, we are scaling our manufacturing right here in Kitchener. We are ready to take this Kitchener-Waterloo-born innovation to the rest of the world.”
This week, Vena announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the use of its Vena MicroAngioscope System in the peripheral vasculature.
Velocity is Waterloo’s flagship incubator and offers mentorship, funding and Canada’s largest tech-corridor network to help creators move ideas from the lab to the marketplace. Since 2008, Velocity has helped launch more than 500 startups that together exceed $40 billion in enterprise value.

Read more
Expanded Health Sciences Campus to bolster regional economy and profile

Read more
New initiative linked to the Velocity entrepreneurship ecosystem to support health-tech startups

Read more
Waterloo spinoff company wins Health Canada licence for innovative X-ray technology
The University of Waterloo acknowledges that much of our work takes place on the traditional territory of the Neutral, Anishinaabeg, and Haudenosaunee peoples. Our main campus is situated on the Haldimand Tract, the land granted to the Six Nations that includes six miles on each side of the Grand River. Our active work toward reconciliation takes place across our campuses through research, learning, teaching, and community building, and is co-ordinated within the Office of Indigenous Relations.